Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastrointest Oncol. Apr 15, 2016; 8(4): 410-415
Published online Apr 15, 2016. doi: 10.4251/wjgo.v8.i4.410
Table 1 Clinicopathologic findings of middle, proximal and distal third gastric carcinoma patients
VariablesMGC (n = 919) (%)PGC (n = 312) (%)DGC (n = 2000) (%)P value
Age (mean, yr)55.8 ± 11.755.8 ± 12.557.6 ± 10.7< 0.001
Gender0.277
Male602 (65.5)219 (70.2)1327 (66.4)
Female317 (34.5)93 (29.8)673 (33.6)
Tumor size (mean, cm)4.2 ± 2.84.7 ± 2.63.7 ± 2.3< 0.001
Depth of invasion< 0.001
T1296 (32.2)41 (13.1)648 (32.4)
T2112 (12.2)45 (14.4)307 (15.4)
T3410 (44.6)177 (56.8)844 (42.2)
T4101 (11.0)49 (15.7)201 (10.0)
Histologic type< 0.001
Differentiated324 (35.3)108 (34.6)941 (47.1)
Undifferentiated595 (64.7)204 (65.4)1059 (52.9)
Lymph node dissection0.018
< D2215 (23.4)51 (16.3)475 (23.7)
≥ D2704 (76.6)261 (83.7)1525 (76.3)
Lymph node metastasis0.045
N (-)561 (61.1)125 (40.1)1217 (60.9)
N (+)358 (38.9)187 (59.9)783 (39.1)
Operative type< 0.001
Total gastrectomy297 (32.3)267 (85.6)75 (3.8)
Others622 (67.7)45 (14.4)1925 (96.2)
Hepatic metastasis0.068
H (-)899 (97.8)300 (96.2)1914 (95.7)
H (+)20 (2.2)12 (3.8)86 (4.3)
Peritoneal dissemination0.556
P (-)838 (91.2)282 (90.4)1829 (91.4)
P (+)81 (8.8)30 (9.6)171 (8.6)
Stage< 0.001
I356 (38.7)71 (22.7)840 (42.0)
II167 (18.2)66 (21.2)322 (16.1)
III223 (24.3)109 (34.9)432 (21.6)
IV173 (18.8)66 (21.2)406 (20.3)
Curability0.796
Curative764 (83.1)254 (81.4)1658 (82.9)
Non-curative155 (16.9)58 (18.6)342 (17.1)
Table 2 Univariate analysis of prognostic factors in middle third gastric carcinoma patients
VariablesNo. of patients5-yr survival rateP value
Age0.0057
< 6568856.0
≥ 6523140.0
Gender0.0161
Male60248.9
Female31759.9
Tumor size (cm)< 0.001
< 561668.5
≥ 530328.0
Depth of invasion< 0.001
T129688.3
T211275.9
T341037.8
T410115.4
Histologic type0.0294
Differentiated32462.8
Undifferentiated59548.2
Hepatic metastasis< 0.001
(-)89953.7
(+)2010.8
Operative type0.4327
Total29752.4
Others62263.6
Lymph node invasion< 0.001
N (-)56177.5
N (+)35832.7
Lymph node dissection< 0.001
< D221518.3
≥ D270460.0
Stage< 0.001
I35687.5
II16762.5
III22335.2
IV17314.7
Table 3 Influence of T category, and N category on the 5-year survival rate of patients with middle third gastric carcinoma surgically treated with curative intent
VariablesPGC (n = 254) (%)MGC (n = 764) (%)P value
Depth of invasion
T177.688.80.0477
T276.076.10.7534
T344.645.10.9900
T417.316.80.1698
Lymph node metastasis
N072.379.90.0270
N142.749.60.6285
N233.431.00.6933
Stage
I77.287.90.0420
II68.463.20.5566
III33.736.30.5823
IV17.621.80.3635
Table 4 Multivariate analysis of survival for middle third gastric carcinoma patients
VariablesRisk ratio95%CIP value
Age (< 65 vs≥ 65)1.781.24-2.550.002
Tumor size (mm) (< 50 vs≥ 50)1.511.03-2.210.036
Serosal invasion (negative vs positive)2.461.45-4.150.001
Lymph node metastasis (negative vs positive)2.481.59-3.870.000
Curability (curative vs non-curative)3.462.29-5.23< 0.001